Pay in 4 interest-free payments of $6.63 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Clinical studies reveal Wegovy aids in shedding an average of 15% of body weight over approximately 68 weeks
For patients using insurance or manufacturer savings programs, ask whether the replacement will affect your allowed refills or require additional prior authorization
Event Phase 2 Rate (12 mg group) Phase 2 Rate (Placebo) Nausea 45.8% 11.6% Diarrhea 33.3% 9.3% Vomiting 22.2% 2.3% Constipation 16.7% 7.0% Decreased appetite 22.2% 2.3% The nausea incidence at the highest dose a nausea percentage of roughly 46% makes it the single most reported adverse event in retatrutide clinical trials 2026 data
The registered nurse can advise on symptom management strategies
